56 patents
Utility
Modified Ipscs
18 Jan 24
The present invention provides a modified induced pluripotent stem cell iPSC or haemogenic lineage cell comprising at least one heterologous nucleic acid sequence encoding a heterologous T-cell receptor (TCR) integrated in the cell genome and uses thereof.
Garth HAMILTON, Christine SEIDL
Filed: 11 May 21
Utility
T Cell Receptors
11 Jan 24
The present invention relates to T cell receptors (TCRs) which bind the HLA-A*0201 restricted peptide GVYDGEEHSV (SEQ ID NO: 1) derived from the MAGE-B2 protein.
Nicholas Tribble, Eleanor Bagg, William Lawrance
Filed: 1 Aug 23
Utility
Method of Treatment of Cancer or Tumour
7 Dec 23
The present invention relates to a method of treating, preventing or delaying the progression of cancer and/or tumour in a subject comprising administering to the subject a treatment regimen comprising an effective amount of modified immunoresponsive cells expressing or presenting a heterologous T-cell receptor (TCR) having the property of binding to Fetoprotein (AFP) or antigenic peptide thereof, in particular the treatment of Hepatocellular carcinoma (HCC).
Nicholas Jonathan Pumphrey
Filed: 12 Feb 21
Utility
Peptides Derived from Kita-kyushu Lung Cancer Antigen (KKLC1, CT83, CXORF61) and Complexes Comprising Such Peptides Bound to MHC Molecules
19 Oct 23
The present invention relates to novel peptides derived from Kita-kyushu lung cancer antigen 1 (CT83), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules.
Alex POWLESLAND, Chandramouli CHILLAKURI, Dhaval SANGANI, Graham HOOD, Alina POPA
Filed: 3 Jan 23
Utility
T cell receptors
12 Sep 23
The present invention relates to T cell receptors (TCRs) which bind the HLA-A*0201 restricted peptide GVYDGEEHSV (SEQ ID NO: 1) derived from the MAGE-B2 protein.
Nicholas Tribble, William Lawrance, Eleanor Bagg
Filed: 14 Oct 21
Utility
T cell receptors
15 Aug 23
The present invention relates to T cell receptors (TCRs) which bind the HLA-A*0201 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the MAGE-A4 protein.
Nicholas Tribble, William Lawrance, Eleanor Bagg
Filed: 14 Oct 21
Utility
T Cell Manufacturing Process
4 May 23
The present invention relates to improved methods for manufacturing T cells and improved T cell compositions resulting therefrom.
Katerina Mardilovich
Filed: 14 Oct 22
Utility
T cell receptors
7 Feb 23
The present invention relates to T cell receptors (TCRs) which bind the HLA-A*0201 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the MAGE-A4 protein.
Nicholas Tribble, William Lawrance, Eleanor Bagg
Filed: 17 Aug 22
Utility
T Cell Receptors
26 Jan 23
The present invention relates to T cell receptors (TCRs) which bind the HLA-A*0201 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the MAGE-A4 protein.
Nicholas Tribble, William Lawrance, Eleanor Bagg
Filed: 17 Aug 22
Utility
Method of Treatment of Cancer or Tumour
24 Nov 22
The present invention provides methods of treating, preventing or delaying the progress of cancer and/or tumour in a subject comprising administering to the subject a treatment regimen comprising an effective amount of a PD-1 axis binding antagonist and a population of modified immunoresponsive cells expressing or presenting a heterologous TCR.
Jonathan David Silk, Emily Puo San Lam, Alexandra Sevko, Dennis Robert Williams, Samik Basu
Filed: 13 Jul 22
Utility
Culture Medium for Haematopoietic Induction
1 Sep 22
This invention concerns chemically defined haematopoietic induction media that support the differentiation of haemogenic endothelial cells (HECs) into haematopoietic progenitor cells (MFCs) that are capable of further differentiation into T cells.
Cheng Tao Yang, Lee Carpenter
Filed: 20 Aug 20
Utility
T Cell Production from Rag Inactivated Ipscs
1 Sep 22
This invention relates to the differentiation of recombination activating gene (RAG) inactivated progenitor cells into T cells through the expression of an exogenous T Cell Receptor (TCR).
Laura Jane Barker, Lee Carpenter, Adam Sidaway
Filed: 20 Aug 20
Utility
Lentiviral Transduction Methods
1 Sep 22
This invention relates to methods of transducing mammalian cells that comprise exposing a population of mammalian cells to a poloxamer in the absence of a lentiviral vector for 6 hours or more to produce a transduction-primed mammalian cell population, exposing the transduction-primed mammalian cell population to a lentiviral vector, such that the T cells are transduced with the lentiviral vector; and then separating the transduced mammalian cells from the poloxamer.
Jonathan Silk, Rosanna McEwen-Smith, Nika Japelj, Garth Hamilton
Filed: 20 Aug 20
Utility
Methods of T Cell Production
25 Aug 22
This invention relates to the production of a population of TCR αβ+ T cells by a method comprising (i) differentiating a population of haematopoietic progenitor cells (HPCs) into progenitor T cells and (ii) maturing the progenitor T cells to produce a population of TCR αβ+ T cells.
Claire GUEGUEN
Filed: 20 Aug 20
Utility
Methods of Producing Haemogenic Progenitor Cells from Pluripotent Stem Cells
25 Aug 22
This invention relates to the production of a population of haemogenic progenitor cells by (i) differentiating a population of induced pluri potent stem cells (IPSCs) into mesoderm cells and; (II) differentiating the mesoderm cells to produce a population of haemogenic progenitor cells.
Cheng Tao Yang, Lee Carpenter
Filed: 20 Aug 20
Utility
TCR Libraries
28 Jul 22
The present invention relates to a library of particles, the library displaying a plurality of different T cell receptors (TCRs), wherein the plurality of TCRs may consist essentially of TCRs which may comprise an alpha chain variable domain from a natural repertoire and a beta chain variable domain from a natural repertoire, wherein the alpha chain variable domain may comprise a TRAV12-2 or a TRAV21 gene product and the beta chain variable domain may comprise a TRBV6 gene product.
Bent Karsten Jakobsen, Peter Eamon Molloy, Annelise Brigitte Vuidepot, Nathaniel Ross Liddy
Filed: 12 Apr 22
Utility
CorrectedPeptides Derived from Transient Receptor Potential Cation Channel Subfamily M Member 1 (TRPM1), Complexes Comprising Such Peptides Bound to MHC Molecules
9 Jun 22
The present invention relates to novel peptides derived from Transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules.
Alex POWLESLAND, Maurits KLEIJNEN, Meidai SUN
Filed: 7 Aug 20
Utility
T Cell Receptors
28 Apr 22
The present invention relates to T cell receptors (TCRs) which bind the HLA-A*0201 restricted peptide GVYDGEEHSV (SEQ ID NO: 1) derived from the MAGE-B2 protein.
Nicholas Tribble, William Lawrance, Eleanor Bagg
Filed: 12 Jan 22
Utility
T cell receptors
29 Mar 22
The present invention relates to T cell receptors (TCRs) which bind the HLA-A*0201 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the MAGE-A4 protein.
Nicholas Tribble, William Lawrance, Eleanor Bagg
Filed: 8 Oct 18
Utility
T Cell Modification and Use Thereof
3 Mar 22
This invention relates to modified T cells that inducibly express a bioactive molecule, such as IL-7, and constitutively expresses an antigen receptor, such as a T cell receptor or chimeric antigen receptor that binds to a tumour antigen.
Garth Hamilton, Jonathan Silk, Claire Gueguen
Filed: 7 Sep 21